SCHEMBL4024480

SCHEMBL4024480

Cc1c(F)cccc1C1[C@@H](C(=O)c2cccc(O)c2)CN(CCNCS(N)(=O)=O)C[C@@H]1C(=O)c1cccc(O)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 4/20 0.35
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
OPRM1 P35372 2/20 0.31
OPRD1 P41143 2/20 0.31
DRD4 P21917 2/20 0.31
DRD2 P14416 2/20 0.31
HTR1A P08908 1/20 0.31
DRD1 P21728 1/20 0.31
DRD5 P21918 1/20 0.31
DRD3 P35462 1/20 0.31
MCHR1 Q99705 1/20 0.31
OPRK1 P41145 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
KCNH2 Q12809 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024482 1.00 KDM2B (0.35) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL4029451 0.87 CARM1 (0.37) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL4021154 0.86 KDM4E (0.34) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL4024718 0.86 KDM4E (0.34) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL13721491 0.86 KDM4E (0.34) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL13720775 0.86 MEN1 (0.35) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL4024540 0.86 MEN1 (0.35) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL4024525 0.86 MEN1 (0.35) KDM2BMEN1KMT2AOPRM1OPRD1
SCHEMBL4025235 0.85 OPRM1 (0.35) KDM2BMEN1KMT2AOPRM1DRD4
SCHEMBL4025226 0.85 OPRM1 (0.35) KDM2BMEN1KMT2AOPRM1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KDM2B 3090/4885MEN1 77/4885KMT2A 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.